developed the behavioural variant frontotemporal dementia phenotype. The only factor associated with conversion to dementia was MCI diagnosis at baseline ( p = 0.023). Conclusion: Cognitive decline occurs in a great proportion of PSP-RS patients early during the disease course. In the absence of a specific phenotype, the diagnosis of MCI might identify PSP patients at greatest risk of developing dementia and should be considered further in the diagnostic assessment.
To date, however, the prevalence, clinical features, and progression of cognitive disturbances in PSP have been poorly described [6, 7] . In this context, the nosological entity of mild cognitive impairment (MCI) [8] , introduced to identify subjects with increased risk of developing dementia, has not yet been applied in PSP cases.
In the present naturalistic retrospective study, we assessed the cognitive and behavioural performances in a large cohort of PSP patients, identifying the prevalence of subjects with MCI and/or dementia, and analysed the predictors of progression to dementia over time.
Methods

Patient Selection
The study included patients with a diagnosis of probable PSP with Richardson syndrome (PSP-RS) [1, 3] , consecutively recruited at the Centre for Neurodegenerative Disorders, University of Brescia, Italy, from January 2001 to June 2016.
All subjects underwent a routine laboratory analysis and brain MRI structural imaging study, as well as extensive neuropsychological assessment. According to neuropsychological performances, each patient was classified as (i) PSP with normal cognition (PSP-NC), (ii) PSP with MCI (PSP-MCI), or (iii) PSP with dementia (PSP-D).
MCI was defined as an impairment in at least 2 neuropsychological tests (score below 1.5 standard deviation cut-off) with no impairment of Instrumental Activities of Daily Living (IADL) and Basic Activities of Daily Living (BADL) [8, 9] . Dementia was defined as cognitive/behavioural decline with insidious onset with impairment of BADL and/or IADL, not depending on motor function. Behavioural variant frontotemporal dementia (bvFTD) was defined according to the current clinical criteria [10] .
The same neuropsychological assessment performed at baseline was carried out each year, when possible; patients with at least a 3-year follow-up were considered for evaluating the progression of cognitive dysfunction.
This study was approved by the Brescia Hospital Ethics Committee and was in conformity with the Helsinki Declaration. Informed consent was obtained from all participants.
Clinical, Neuropsychological, and Behavioural Assessment
Each patient underwent a general medical and neurological evaluation and neuropsychological assessment at enrolment and at follow-up. Motor function was assessed by the motor part of the Unified Parkinson Disease Rating Scale (UPDRS-III); the PSP rating scale (PSP-RS) was not adopted in the present study as initially introduced in 2007 [11] .
The neuropsychological assessment included the Mini-Mental State Examination (MMSE) (global cognition), the Verbal and Category Fluency test, the Token test (language function), the Clock Drawing test, the copy of the Rey Complex Figure ( . Behavioural disturbances were evaluated by the Neuropsychiatric Inventory (NPI) and the Frontal Behavioural Inventory (FBI) [12] .
Statistical Analyses
Baseline demographic characteristics and cognitive and behavioural scores were compared by the Kruskal-Wallis or χ 2 test, as appropriate. Significance was set at p < 0.05 for demographics and clinical scores, and at p < 0.004 for neuropsychological testing (adjusted for multiple comparisons). The rate of progression of each cognitive and behavioural variable was calculated between the first and second visit. One-sample Student t test was applied to determine whether the 1-year worsening score was significantly different from zero, and an estimation of the 95% confidence intervals (CIs) was performed. Predictors of conversion to dementia were evaluated by logistic regression analysis. The odds ratios (ORs) and 95% CIs were determined. Data analyses were carried out using SPSS 22.0 software (IBM Corp., Armonk, NY, USA).
Results
Clinical Features and Cognitive Diagnosis at Baseline
Ninety-nine PSP-RS patients were evaluated in the study. The mean age was 73.7 ± 5.5 years, and the mean disease duration was 3.3 ± 2.1 years. Forty-nine patients (49%) were female, and a family history of neurodegenerative disorders was reported in 30 cases (30%). No patients with monogenic MAPT mutations were included. Motor impairment, as measured by the UPDRS-III score, was 27.4 ± 13.8 points.
At baseline, the assessment of cognitive performances and functional abilities allowed us to subgroup PSP patients into 15 PSP-NC (15.2%), 43 PSP-MCI (43.4%), and 41 PSP-D (41.4%). As reported in Table 1 , there were no differences in demographic variables. The neuropsychological and behavioural assessments showed significantly worse performances in PSP-D and, to a lesser extent, in PSP-MCI compared to PSP-NC. The differences were still significant after correction for the degree of motor impairment, as measured by the UPDRS-III total score. PSP-D patients had greater deficits in planning and visual-spatial abilities (copy of the Rey Figure, 85% , and Clock Drawing test, 92%) and executive functions (Trail Making A, 61%, and Trail Making B, 83%) along with language deficits (both comprehension and production). Eighteen PSP-D patients (44%) fulfilled the criteria for bvFTD.
PSP-MCI patients had greater deficits in planning (copy of the Rey Figure, 75% , and Clock Drawing test, 56%) and frontal executive functions (Trail Making A, 51%). Almost all PSP-MCI patients (95%) had non-amnestic MCI.
The 3 subgroups did not differ in the severity of behavioural disturbances. Overall, the most common behavioural symptom was apathy (56%) followed by loss of empathy (24%), disinhibition (17%), perseveration (13%), and binge eating (11%).
Conversion to Dementia over Time
Forty-seven PSP-RS patients completed the 3-year follow-up. Eighteen out of 47 (38%) were already classified as PSP-D at baseline, whilst 29 were not (9 PSP-NC and 20 PSP-MCI). There were no differences in demographic characteristics, cognitive impairment, or motor function between these patients and those who dropped out (data not shown).
The rate of annual progression in cognitive tests and behavioural scales is shown in online supplementary Table 1 (see www.karger.com/doi/10.1159/000479110 for all online suppl. material). The analyses of progression rates showed significantly different scores after 1 year of follow-up in MMSE, Trail Making B, FBI-A, FBI total score, as well as BADL/IADL evaluation. The total UP-DRS-III scores and the other cognitive tests did not significantly differ from the first visit to the 1-year follow-up (see online suppl. Table 1 ). Results are expressed as mean ± standard deviation (percentage of subjects with pathological scores -corrected for age and education -in parentheses), unless otherwise indicated. BADL, Basic Activities of Daily Living; FBI, Frontal Behavioural Inventory; FBI-A, negative behaviour score of the FBI; FBI-B, positive behaviour score of the FBI; IADL, Instrumental Activities of Daily Living; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; PSP, progressive supranuclear palsy; PSP-NC, PSP patients with normal cognition; PSP-MCI, PSP patients with mild cognitive impairment, PSP-D, PSP patients with dementia; UPDRS-III, motor assessment of the Unified Parkinson Disease Rating Scale. * Kruskal-Wallis test, unless otherwise specified; ** χ 2 test, PSP-NC vs. PSP-MCI vs. PSP-D. Figure 1 shows the conversion to dementia during follow-up. Overall, 84% of the 47 patients who completed the follow-up had dementia after 3 years. The conversion rate to dementia was 72% (21 out of 29 patients with PSP-NC or PSP-MCI) with a mean disease duration at conversion of 5.2 ± 1.4 years (15 patients converted at the 1-year follow-up, 3 at the 2-year follow-up, and another 3 at the 3-year follow-up). This corresponds to an incidence rate of 241 per 1,000 patients/year. Nineteen out of 21 PSP patients (90%) who converted to dementia fulfilled the criteria for bvFTD, while 2 out of 21 presented multi-domain impairment with no major behavioural disturbances. No patients developed corticobasal syndrome, primary progressive aphasia, or Alzheimer's disease features.
PSP patients who developed dementia during the 3-year follow-up had later disease onset than PSP patients who did not develop dementia (70.5 ± 5.8 vs. 64.5 ± 7.0, p = 0.03; OR for age at onset >70 = 11.3, 95% CI: 1.2-110.4, p = 0.036), and had greater prevalence of MCI at baseline (91 vs. 25%, p < 0.001; OR = 33.2, 95% CI: 3.9-283, p = 0.004) (see online suppl. Fig. 1) . Conversely, the 2 groups were comparable for degree of motor impairment and the other demographic variables. In a regression analysis model, MCI at baseline was the only predictor of conversion to dementia (regression analysis, p = 0.03) compared to age at onset ( p = 0.06).
Discussion
The core features of "classical PSP criteria" are represented by a progressive akinetic-rigid syndrome with vertical gaze palsy, falls, and bulbar symptoms. In the new PSP criteria, the assessment of cognitive impairment has been introduced in the diagnostic work-up in order to define the different variants of PSP [3] . This was prompted by the frequent overlap with FTD symptoms, thus considering frontal presentation, language deficits, or corticobasal syndrome as new key features in defining probable or possible PSP [3, 4] .
The present study assessed cognitive and behavioural performances in a large series of PSP-RS patients to evaluate the prevalence, the associated clinical features, and their relevance in the PSP clinical picture. We reported that a great proportion of cases presented with dementia already at the time of diagnosis (41.4%), mainly resembling bvFTD. However, a consistent number of cases (43.4%) presented subtle cognitive dysfunction, fulfilling current non-amnestic MCI criteria [13] . Of note, only a small group of patients (15.2%) had normal cognition at baseline, further highlighting that cognitive impairment represents a significant feature in PSP.
Along with cognitive dysfunction, PSP was further characterized by different behavioural deficits: apathy, loss of empathy, disinhibition, and binge eating were the most frequently reported. Our findings confirmed and extended previous crosssectional studies claiming the presence of cognitive impairment, prominently in the executive domain, in most PSP patients [4, 6, [14] [15] [16] [17] [18] . The present study showed that the number of PSP patients with dementia dramatically increased over time, involving more than 80% of PSP patients after 3 years. This resulted in a dementia incidence rate of 241 per 1,000 patients/year, 3 times higher than Parkinson disease [15] .
These results further support the importance of considering cognitive dysfunction in the assessment of PSP, but also highlight the need to consider "frontal presentation" as supportive of PSP diagnosis in the current criteria. This, indeed, may change the accuracy of PSP diagnosis, depending on the presence of this clinical feature.
We introduced the concept of MCI in the realm of atypical parkinsonism, and we reported that a great proportion of patients presented MCI at the time of diagnosis. Non-amnestic MCI was the only predictive factor of dementia development in PSP, with an increased risk of more than 30 times (OR = 33.2). Thus, it remains to be elucidated how non-amnestic MCI should be considered as a supportive criterion of PSP with predominant frontal presentation, as included in the revised criteria [3] . Conversely, the stage of motor impairment did not predict conversion to dementia.
Despite the large sample size and the long follow-up, the study entails some limitations. The retrospective nature of data collection did not allow the evaluation of PSP-RS [15, 19] or advanced clinical [18, 20] , imaging [21, 22] , and biological markers [23] in predicting dementia over time. Furthermore, cognition and motor dysfunction are strongly related, and several neuropsychological tests might be impaired because of motor dysfunction. However, total UPDRS-III and disease duration (both proxies of disease severity) did not statistically differ between the PSP-N and PSP-MCI groups and suggest that these groups might represent different PSP phenotypes and not just different time points of classical PSP syndrome.
Overall, these findings confirm the central role of cognition in PSP, and argue that even subtle cognitive deficits need to be taken into account in the diagnostic assessment [12] . The application of the label of MCI may identify those subjects who are at higher risk of converting to dementia and should be further evaluated in the diagnostic algorithm together with the upcoming new classification of PSP syndromes.
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